Xianhai Huang

USPTO Granted Patents = 49 (Patent Applications = 26)

CIPO Patents = 1

EPO Patents = 27 (Patent Applications = 37)

Average Co-Inventor Count = 10.4

ph-index = 5

Forward Citations = 98(Granted Patents)

Company Filing History:

34 out of 2,405

Merck Sharp + Dohme Corp.

Msd R&d (china) Co., Ltd.

patents

5. 1 out of 1,186

The Scripps Research Institute

patents

6. 4 out of 832,680

Other

patents

where one patent can have more than one assignee

Years Active: 2006-2025

Loading Chart...

49 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12264134 - Substituted piperazine amide compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors (2025-04-01),

2. 12065438 - Substituted tricyclic compounds as indoleamine 2,3-dioxygenase inhibitors (2024-08-20),

3. 11478461 - [1.1.1] bicyclo compounds as indoleamine 2,3-dioxygenase inhibitors (2022-10-25),

4. 11433055 - Chromane monobactam compounds for the treatment of bacterial infections (2022-09-06),

5. 11352320 - Substituted [1.1.1] bicyclo compounds as indoleamine 2,3-dioxygenase inhibitors (2022-06-07),

6. 11230543 - Biaryl monobactam compounds and methods of use thereof for the treatment of bacterial infections (2022-01-25),

7. 10822338 - Substituted aminoquinazoline compounds as Aantagonist (2020-11-03),

8. 10759805 - Compounds that are ERK inhibitors (2020-09-01),

9. 10442819 - Tricyclic compounds as inhibitors of mutant IDH enzymes (2019-10-15),

10. 10407421 - Bicyclic aryl monobactam compounds and methods of use thereof for the treatment of bacterial infections (2019-09-10),

11. 10399972 - Tricyclic compounds as inhibitors of mutant IDH enzymes (2019-09-03),

12. 10065967 - Compounds that are ERK inhibitors (2018-09-04),

13. 10011615 - Heterobicyclo-substituted [1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with A2A anatagonist properties (2018-07-03),

14. 9988397 - ERK inhibitors (2018-06-05),

15. 9969711 - [object Object] (2018-05-15),

Title: Xianhai Huang: Innovator in Indoleamine 2,3-Dioxygenase Inhibitors

Introduction

Xianhai Huang is an accomplished inventor based in Warren, NJ, who has made significant contributions to the field of pharmaceuticals, particularly in the development of indoleamine 2,3-dioxygenase (IDO) inhibitors. With an impressive portfolio of 48 patents, Huang's work has paved the way for potential treatments targeting IDO-associated diseases or disorders.

Latest Patents

Huang's recent patents focus on substituted tricyclic compounds and bicyclo compounds as IDO inhibitors. The patents disclose compounds of formula (I), which inhibit the IDO enzyme. Additionally, these documents outline the potential uses of these compounds in the treatment or prevention of various IDO-associated diseases or disorders. Furthermore, the compositions comprising these compounds are also detailed, emphasizing their prospective therapeutic applications.

Career Highlights

Throughout his career, Xianhai Huang has worked at prominent companies in the pharmaceutical industry, including Merck Sharp & Dohme Corporation and Opko Health, Inc. His roles in these organizations have contributed to the advancement of innovative treatments and therapeutic strategies, solidifying his reputation as a leader in his field.

Collaborations

Huang has collaborated with notable individuals such as Anandan Palani and Dong Xiao, sharing expertise and fostering innovation within their respective projects. These partnerships highlight the importance of teamwork in the development of new pharmacological solutions.

Conclusion

Xianhai Huang's dedication to research and innovation has led to the creation of crucial patents in the realm of IDO inhibitors. His achievements not only contribute to the scientific community but also hold promise for improving treatment options for various diseases. As his work continues to evolve, Huang remains a key figure in advancing pharmacological research and development.

This text is generated by artificial intelligence and may not be accurate.